Recursion says REC-617 demonstrates dose-linear pharmacokinetics with rapid absorption and robust pharmacodynamic biomarker modulation. Recursion holds a webinar on Tuesday to discuss results from the ...

Recursion announces that it intends to offer and sell 30,769,230 shares of its common stock for $6.50 per share. Recursion expects to receive total gross proceeds of approximately $200 million. See ...

CEO Chris Gibson highlighted the company's strategic focus on the Recursion Operating System 2.0, emphasizing its capability to improve efficiency in drug discovery and development. Management ...

Unmet clinical needs often serve as the fundamental driving force behind drug discovery programs. During lead discovery, an intensive search ensues to find a drug-like small molecule or biological ...

One way to think about artificial intelligence, in its modern deep learning form, is as a jigsaw puzzle. You have a picture on the box, and you begin to organize your pieces. "I usually start by ...

SAN MATEO, Calif.--(BUSINESS WIRE)--Helix, a leading population genomics company and provider of precision medicine genomics solutions, today announced a groundbreaking multi-year agreement with ...

Recursion Pharmaceuticals is an AI-enabled drug discovery company, differentiated by its scale and focus on understanding biology. The company has a broad pipeline across various therapeutic areas and ...

BioHive-2, an NVIDIA DGX SuperPOD with NVIDIA DGX H100 systems, ranked #35 in the TOP500 list of the most powerful supercomputers in the world across all industries as of May 2024. SALT LAKE CITY, May ...

Investors looking for an exciting clinical-stage biotech start-up with enormous potential should be paying close attention to Recursion Pharmaceuticals (NASDAQ: RXRX). The company has emerged as a ...

Success for just one of Recursion's phase 2 programs could enable the stock to double within five years. However, the odds of success for phase 2 candidates aren't good. Risk-averse investors should ...